Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Eptifibatide powder injection

A technology of tebatide powder and eptifibatide, which is applied in the direction of cyclic peptide components, powder delivery, medical preparations of non-active ingredients, etc., can solve the problems of difficulty, cost increase, high freeze-drying, etc., and achieve transportation and storage Convenience, reduce production cost, improve stability

Inactive Publication Date: 2010-02-03
NANJING CHANGAO PHARMA SCI & TECH CO LTD
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The solubility of Efibuta in water is low. When the pH value reaches 7, it is easy to precipitate out of the solution. The general co-solvent has little effect on its solubility, and has certain viscosity and aggregation. Therefore, the maximum concentration of the infusion solution is generally 20mg / ml, so that the volume of the same dose of efibat injection for each patient will be very large, so that even if a large dose bottle of 100ml: 200mg is given, more than 2 bottles will be needed. Need to occupy a larger space, and the cost will increase accordingly
In addition, efibat has poor stability in aqueous solution, and when the pH value is lower than 4, the related substances increase significantly
At the same time, in the process of preparation, high temperature will reduce the activity of eptifibatide, and the high viscosity makes it difficult to freeze-dry the drug preparation.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Eptifibatide powder injection

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0026] Embodiment 1 20mg specification formula

[0027] Eptifibatide 20.0g

[0028] Citric acid 25.0g

[0029] Lactose 50.0g

[0030] 1MNaOH appropriate amount

[0031] Water for injection to 1500ml

[0032] Makes 1000 bottles

Embodiment 2

[0033] Embodiment 2 20mg specification formula

[0034] Eptifibatide 20.0g

[0035] Citric acid 28.0g

[0036] Lactic acid 2.0g

[0037] Lactose 50.0g

[0038] Mannitol 50.0g

[0039] 1MNaOH appropriate amount

[0040] Water for injection to 1500ml

[0041] Makes 1000 bottles

Embodiment 3

[0042] Embodiment 3 20mg specification formula

[0043] Eptifibatide 20.0g

[0044] Sodium citrate 30.0g

[0045] Mannitol 120.0g

[0046] 1M HCl qs

[0047] Water for injection to 2000ml

[0048] Makes 1000 bottles

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of medicinal preparations and relates to an eptifibatide powder injection, which mainly comprises eptifibatide, carbohydrates and an acidity regulator. The eptifibatide powder injection has the characteristics of high concentration and good stability, can be used for treating acute coronary syndrome including unstable angina pectoris and non-Q wave infarction andcan also be used in percutaneous coronary intervention including angioplasty and atherectomy.

Description

technical field [0001] The invention belongs to the field of pharmaceutical preparations and relates to eptifibatide powder injection. Background technique [0002] Eptifibatide (Efibate) is a glycoprotein II b / IIIa receptor antagonist, which binds to the GPIIb / IIIa receptor on the platelet membrane and occupies the binding site on it, allowing the platelet GPIIb / IIIa receptor The body cannot bind to fibrinogen, thereby inhibiting platelet aggregation. Clinically indicated for the treatment of acute coronary syndromes, including unstable angina or non-Q-wave myocardial infarction (ie, persistent episodes of chest pain within 24 hours, ECG changes, and / or elevated cardiovascular system enzymes); also for percutaneous coronary use Interventional therapy, including angioplasty or atherectomy. In July 1998, it was first listed in the United States under the trade name Intrifiban by Schering-Plough Company, and in 1999 it was launched in Europe under the trade name Intrifiban. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K9/19A61K38/12A61K47/26A61K47/10A61K47/12A61P9/10
Inventor 谢晓燕张自强黄海燕
Owner NANJING CHANGAO PHARMA SCI & TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com